Medtronic plc Net Assets
Medtronic plc net assets. Based on the latest financial reports, Medtronic plc (MDTC34) has net assets worth R$50.07 Billion BRL (≈ $9.83 Billion USD) as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$93.03 Billion ≈ $18.25 Billion USD) and total liabilities (R$42.96 Billion ≈ $8.43 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Medtronic plc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$50.07 Billion |
| % of Total Assets | 53.82% |
| Annual Growth Rate | -0.04% |
| 5-Year Change | -5.03% |
| 10-Year Change | N/A |
| Growth Volatility | 2.66 |
Net Assets of Medtronic plc (2019–2026)
Net assets of Medtronic plc from 2019 to 2026. This chart illustrates how Medtronic plc's net assets have evolved over time, based on quarterly financial data. See MDTC34 equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Medtronic plc (2019–2026)
The table below shows the annual net assets of Medtronic plc from 2019 to 2026. For live market cap and overall valuation, see MDTC34 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | R$50.07 Billion ≈ $9.83 Billion |
+3.76% |
| 2025-04-30 | R$48.26 Billion ≈ $9.47 Billion |
-3.90% |
| 2024-04-30 | R$50.21 Billion ≈ $9.85 Billion |
-2.46% |
| 2023-04-30 | R$51.48 Billion ≈ $10.10 Billion |
-2.35% |
| 2022-04-30 | R$52.72 Billion ≈ $10.35 Billion |
+2.17% |
| 2021-04-30 | R$51.60 Billion ≈ $10.13 Billion |
+1.43% |
| 2020-04-30 | R$50.87 Billion ≈ $9.98 Billion |
+1.31% |
| 2019-04-30 | R$50.21 Billion ≈ $9.85 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medtronic plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 102.7% over the analyzed period, indicating profitable operations and earnings retention.
Medtronic plc Net Assets Breakdown (April 2026)
Medtronic plc net assets breakdown by equity component as of April 2026.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$32.64 Billion | 65.98% |
| Other Components | R$16.82 Billion | 34.02% |
| Total Equity | R$49.46 Billion | 100.00% |
Medtronic plc Competitors by Market Cap
The table below lists competitors of Medtronic plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Life Insurance Co Ltd A
SHG:601628
|
$105.43 Billion |
|
Sanofi
F:SNW2
|
$105.72 Billion |
|
Lockheed Martin Corporation
NYSE:LMT
|
$106.03 Billion |
|
Snowflake Inc.
NYSE:SNOW
|
$106.09 Billion |
|
Marriott International Inc
NASDAQ:MAR
|
$104.66 Billion |
|
AIR LIQUIDE ADR 1/5/EO 11
F:AILA
|
$103.86 Billion |
|
INTESA SANPAOLO ADR/6
F:IESJ
|
$103.85 Billion |
|
Pinduoduo Inc
F:9PDA
|
$102.48 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medtronic plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 48,024,000,000 to 49,463,000,000, a change of 1,439,000,000 (3.0%).
- Net income of 4,801,000,000 contributed positively to equity growth.
- Dividend payments of 3,639,000,000 reduced retained earnings.
- Share repurchases of 1,035,000,000 reduced equity.
- New share issuances of 1,054,000,000 increased equity.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$4.80 Billion | +9.71% |
| Dividends Paid | R$3.64 Billion | -7.36% |
| Share Repurchases | R$1.03 Billion | -2.09% |
| Share Issuances | R$1.05 Billion | +2.13% |
| Other Changes | R$258.00 Million | +0.52% |
| Total Change | R$- | 3.00% |
Book Value vs Market Value Analysis
This analysis compares Medtronic plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.58x to 5.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-04-30 | R$37.36 | R$208.39 | x |
| 2020-04-30 | R$37.83 | R$208.39 | x |
| 2021-04-30 | R$38.23 | R$208.39 | x |
| 2022-04-30 | R$39.49 | R$208.39 | x |
| 2023-04-30 | R$38.69 | R$208.39 | x |
| 2024-04-30 | R$38.29 | R$208.39 | x |
| 2025-04-30 | R$37.46 | R$208.39 | x |
| 2026-04-30 | R$38.64 | R$208.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medtronic plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.71%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.20%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.88x
- Recent ROE (9.71%) is above the historical average (8.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 9.25% | 15.16% | 0.34x | 1.79x | R$-378.10 Million |
| 2020 | 9.44% | 16.56% | 0.32x | 1.79x | R$-284.70 Million |
| 2021 | 7.01% | 11.97% | 0.32x | 1.81x | R$-1.54 Billion |
| 2022 | 9.59% | 15.90% | 0.35x | 1.73x | R$-216.10 Million |
| 2023 | 7.30% | 12.03% | 0.34x | 1.77x | R$-1.39 Billion |
| 2024 | 7.32% | 11.36% | 0.36x | 1.79x | R$-1.35 Billion |
| 2025 | 9.71% | 13.90% | 0.37x | 1.91x | R$-139.40 Million |
| 2026 | 9.71% | 13.20% | 0.39x | 1.88x | R$-145.30 Million |
Industry Comparison
This section compares Medtronic plc's net assets metrics with peer companies in the Medical Devices industry.
No peer company data available for comparison.
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor sy… Read more